共 50 条
- [21] The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade TherapyFRONTIERS IN ONCOLOGY, 2021, 11Russell, Bonnie L.Sooklal, Selisha A.Malindisa, Sibusiso T.Daka, Lembelani JonathanNtwasa, Monde
- [22] Targeting dual gene delivery nanoparticles overcomes immune checkpoint blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapyNANO TODAY, 2021, 38Feng, YuanjiWu, JiayanChen, JieLin, LinZhang, SijiaYang, ZhiyuSun, PingjieLi, YanhuiTian, HuayuChen, Xuesi
- [23] Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistanceIMMUNOLOGY LETTERS, 2020, 220 : 88 - 96Li, YaqiLiu, JingGao, LongLiu, YuanMeng, FangLi, XiaoanQin, F. Xiao-Feng
- [24] The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironmentFRONTIERS IN IMMUNOLOGY, 2023, 14Luo, HongWang, WenxiangMai, JiaYin, RutieCai, XuyuLi, Qintong
- [25] Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade ImmunotherapySCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (226)Zamarin, DmitriyHolmgaard, Rikke B.Subudhi, Sumit K.Park, Joon SeokMansour, MenaPalese, PeterMerghoub, TahaWolchok, Jedd D.Allison, James P.
- [26] Combination of radiotherapy and vaccination overcomes checkpoint blockade resistanceONCOTARGET, 2016, 7 (28) : 43039 - 43051Zheng, WenxinSkowron, Kinga B.Namm, Jukes P.Burnette, ByronFernandez, ChristianArina, AinhoaLiang, HuaSpiotto, Michael T.Posner, Mitchell C.Fu, Yang-XinWeichselbaum, Ralph R.
- [27] Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistanceJOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (11): : 6109 - 6123Gauttier, VanessaPengam, SabrinaDurand, JustineBiteau, KevinMary, CarolineMorello, AuroreNeel, MelaniePorto, GeorgiaTeppaz, GeraldineThepenier, VirginieDanger, RichardVince, NicolasWilhelm, EmmanuelleGirault, IsabelleAbes, RiadRuiz, CatherineTrilleaud, CharleneRalph, KerryTrombetta, E. SergioGarcia, AlexandraVignard, VirginieMartinet, BernardGlemain, AlexandreBruneau, SarahHaspot, FabienneDehmani, SafaDuplouye, PierreMiyasaka, MasayukiLabarriere, NathalieLaplaud, DavidLe Bas-Bernardet, StephanieBlanquart, ChristopheCatros, VeroniqueGouraud, Pierre-AntoineArchambeaud, IsabelleAuble, HeleneMetairie, SylvieMosnier, Jean-FrancoisCostantini, DominiqueBlancho, GillesConchon, SophieVanhove, BernardPoirier, Nicolas
- [28] Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (vol 29, pg 285, 2016)CANCER CELL, 2016, 30 (03) : 500 - 500Tang, HaidongWang, YangChlewicki, Lukasz K.Zhang, YuanGuo, JingyaLiang, WeiWang, JieyiWang, XiaoxiaoFu, Yang-Xin
- [29] The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint BlockadeCELL REPORTS, 2018, 22 (11): : 2978 - 2994Schaer, David A.Beckmann, Richard P.Dempsey, Jack A.Huber, LysianeForest, AmelieAmaladas, NelushaLi, YanxiaWang, Ying CindyRasmussen, Erik R.Chin, DarinCapen, AndrewCarpenito, CarmineStaschke, Kirk A.Chung, Linda A.Litchfield, Lacey M.Merzoug, Farhana F.Gong, XueqianIversen, Philip W.Buchanan, Seande Dios, AlfonsoNovosiadly, Ruslan D.Kalos, Michael
- [30] T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy SelectionCANCER IMMUNOLOGY RESEARCH, 2018, 6 (09) : 990 - 1000Trujillo, Jonathan A.Sweis, Randy F.Bao, RiyueLuke, Jason J.